Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

Market Cap

$4.35M

MomentumView details →

1D Return

−4.69%

YTD Return

−81.68%

RSI (14)

26.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

Market Cap

$4.35M

RSI (14)

26.5

MomentumView details →

1D Return

−4.69%

YTD Return

−81.68%

SummaryUpdated Jun 1, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Ponte Vedra, Florida. The company went public in January 2023 and focuses exclusively on developing a single therapeutic candidate called Tecarfarin, designed to address a critical unmet medical need in patients with end-stage kidney disease who also suffer from atrial fibrillation.

Ask drillr about Cadrenal Therapeutics, Inc. Common Stock →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−282.13%

ROA (TTM)

−206.55%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+44.88%

FCF YoY

+12.95%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+23.94%

EBITDA YoY

+18.02%

EarningsView details →

EPS (Actual)

−$1.14

EPS Surprise

19.72%

Beats (12Q)

3/12

Next Q EPS Est

−$0.91

Avg Surprise (4Q)

0.72%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.73x

Quick Ratio

3.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.54M

Op. CF (TTM)

−10.16M

Next earningsNov 9, 2026 →

Latest newsMore news →

Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting held on July 28, 2026, regarding its Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.5d ago

Cadrenal Therapeutics announced that Matthew K. Szot departed as Chief Financial Officer by mutual agreement, effective May 28, 2026, and appointed Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer, effective the same date.94d ago

Similar companies

Jupiter Neurosciences, Inc.JUNS GeoVax Labs, Inc.GOVX PMGC Holdings Inc.ELAB XORTX Therapeutics Inc.XRTX Alaunos Therapeutics, Inc.TCRT Mustang Bio, Inc.MBIO Find similar companies →

Latest newsMore news →

Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting held on July 28, 2026, regarding its Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.5d ago Cadrenal Therapeutics announced that Matthew K. Szot departed as Chief Financial Officer by mutual agreement, effective May 28, 2026, and appointed Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer, effective the same date.94d ago